Ke Liu

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 256 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +7

X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome

Ke Liu, Biji T. Kurien, Sarah Zimmerman et al. · Arthritis & Rheumatology · 2015 · 174 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

<i>MIR34A</i>regulates autophagy and apoptosis by targeting<i>HMGB1</i>in the retinoblastoma cell

Ke Liu, Jun Huang, Min Xie et al. · Autophagy · 2014 · 138 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142–3p and miR-129–5p

Ke Liu, Jun Huang, Jiangdong Ni et al. · Cell Cycle · 2017 · 128 citations · Full text

Medicine, Molecular Biology, Oncology +17

CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer

Jin Huang, Pan Chen, Ke Liu et al. · Gut · 2020 · 118 citations

Medicine, Oncology, Pharmacology +17